EXEL Looks 24.3% Overvalued on GF Value™

gurufocus.com · 2026-09-11

On September 11, 2026, Exelixis Inc (NASDAQ: EXEL) announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug ap

Read the full story at gurufocus.com →